» Articles » PMID: 35410981

The Role of Mitochondrial Biogenesis Dysfunction in Diabetic Cardiomyopathy

Overview
Specialty Pharmacology
Date 2022 Apr 12
PMID 35410981
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetic cardiomyopathy (DCM) is described as abnormalities of myocardial structure and function in diabetic patients without other well-established cardiovascular factors. Although multiple pathological mechanisms involving in this unique myocardial disorder, mitochondrial dysfunction may play an important role in its development of DCM. Recently, considerable progresses have suggested that mitochondrial biogenesis is a tightly controlled process initiating mitochondrial generation and maintaining mitochondrial function, appears to be associated with DCM. Nonetheless, an outlook on the mechanisms and clinical relevance of dysfunction in mitochondrial biogenesis among patients with DCM is not completely understood. In this review, hence, we will summarize the role of mitochondrial biogenesis dysfunction in the development of DCM, especially the molecular underlying mechanism concerning the signaling pathways beyond the stimulation and inhibition of mitochondrial biogenesis. Additionally, the evaluations and potential therapeutic strategies regarding mitochondrial biogenesis dysfunction in DCM is also presented.

Citing Articles

Effects of Exercise Training on Cardiac Mitochondrial Functions in Diabetic Heart: A Systematic Review.

Shah I, Ishaq S, Lee S, Wu B Int J Mol Sci. 2025; 26(1.

PMID: 39795867 PMC: 11719559. DOI: 10.3390/ijms26010008.


A Review on the Natural Products in Treatment of Diabetic Cardiomyopathy (DCM).

Yao P, Yang X, Qiao Y Rev Cardiovasc Med. 2024; 25(5):165.

PMID: 39076497 PMC: 11267204. DOI: 10.31083/j.rcm2505165.


Diabetes cardiomyopathy: targeted regulation of mitochondrial dysfunction and therapeutic potential of plant secondary metabolites.

Pan X, Hao E, Zhang F, Wei W, Du Z, Yan G Front Pharmacol. 2024; 15:1401961.

PMID: 39045049 PMC: 11263127. DOI: 10.3389/fphar.2024.1401961.


Roles of Mitochondrial Dysfunction in Diabetic Kidney Disease: New Perspectives from Mechanism to Therapy.

Yang Y, Liu J, Shi Q, Guo B, Jia H, Yang Y Biomolecules. 2024; 14(6).

PMID: 38927136 PMC: 11201432. DOI: 10.3390/biom14060733.


The potential of therapeutic strategies targeting mitochondrial biogenesis for the treatment of insulin resistance and type 2 diabetes mellitus.

Ding W, Yang X, Lai K, Jiang Y, Liu Y Arch Pharm Res. 2024; 47(3):219-248.

PMID: 38485900 DOI: 10.1007/s12272-024-01490-5.


References
1.
Liang Q, Kobayashi S . Mitochondrial quality control in the diabetic heart. J Mol Cell Cardiol. 2016; 95:57-69. PMC: 6263145. DOI: 10.1016/j.yjmcc.2015.12.025. View

2.
Shen X, Zheng S, Thongboonkerd V, Xu M, Pierce Jr W, Klein J . Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. Am J Physiol Endocrinol Metab. 2004; 287(5):E896-905. DOI: 10.1152/ajpendo.00047.2004. View

3.
Karamanlidis G, Nascimben L, Couper G, Shekar P, Monte F, Tian R . Defective DNA replication impairs mitochondrial biogenesis in human failing hearts. Circ Res. 2010; 106(9):1541-8. PMC: 2880225. DOI: 10.1161/CIRCRESAHA.109.212753. View

4.
Ma S, Feng J, Zhang R, Chen J, Han D, Li X . SIRT1 Activation by Resveratrol Alleviates Cardiac Dysfunction via Mitochondrial Regulation in Diabetic Cardiomyopathy Mice. Oxid Med Cell Longev. 2017; 2017:4602715. PMC: 5572590. DOI: 10.1155/2017/4602715. View

5.
Li Y, Wei X, Liu S, Zhao Y, Jin S, Yang X . Salidroside protects cardiac function in mice with diabetic cardiomyopathy via activation of mitochondrial biogenesis and SIRT3. Phytother Res. 2021; 35(8):4579-4591. DOI: 10.1002/ptr.7175. View